The Early-Term Adverse Effects in Healthcare Personnel after CoronaVac Vaccination

Öz

Objectives: Among the various Covidien-19 vaccine, Sinovac vaccination program in Turkey is carried out by coronavac vaccine developed by Chinese firms. Our aim was to determine the early side effects of CoronaVac vaccine in Turkish healthcare professionals. Materials and methods: Volunteer healthcare personnel vaccinated with CoronaVac were evaluated four weeks after the first dose. Demographic, clinical characteristics, and post-vaccination side effects were recorded. Statistical analysis was performed with SPSS 15.0 software. Results: The study was conducted with 516 volunteers. The mean age was 34.53 ± 7.80 years, and the majority of the participants (58.1%) were women. The most common occupational nursing (34.8%) and smoking rate in the study was 27.1%. Approximately one third (31%) of the participants had a previous COVID-19 infection and antibody positivity (27.9%). The most common side effects were determined to be arm pain (55.8%) followed by headache (24.8%), fatigue (18.6%) and joint pain (7.8%). On the third day after vaccination, the diagnosis of COVID-19 was reported in one person. Four (0.8%) stated that they took a break from their daily routine due to syncope and one person due to COVID-19. Conclusion: In this study, no life-threatening side effects were reported in the early period after CoronaVac. Among the early side effects of CoronaVac vaccine in our study, the most common side effects were Arm soreness, Headache, Fatigue and Joint pain. We argue that it is important to use multi-layered and evidence-based strategies to raise the frequency of vaccination and to address the concerns and ownership of the vaccine in relation to the COVID-19 vaccine. In order to minimize widespread information pollution and hostility associated with vaccination, healthcare professionals should lead and strongly support vaccination programs.

Anahtar Kelimeler

• CoronaVac
• COVID-19
• vaccination
• SARS-CoV-2

CoronaVac Aşısı Sonrası Sağlık Personelinde Erken Dönem Olumsuz Etkileri

Öz

Amaç: Çeşitli Covidien-19 aşıları arasında Türkiye'deki Sinovac aşılama programı, Çinli firmalar tarafından geliştirilen coronavac aşısı ile yürütülmektedir. Amacımız CoronaVac aşısının Türk sağlık profesyonellerinde erken yan etkilerini belirlemekti. Metaryal metod: CoronaVac ile aşılanan gönüllü sağlık personeli, ilk dozdan dört hafta sonra değerlendirildi. Demografik, klinik özellikler ve aşılama sonrası yan etkiler kaydedildi. İstatistiksel analiz SPSS 15.0 yazılımı ile yapıldı. Bulgular: Çalışma 516 gönüllü ile gerçekleştirilmiştir. Ortalama yaş 34.53 ± 7.80 yıl olup, katılımcıların çoğunluğu (%58.1) kadındır. Çalışmada en büyük meslek grubu hemşirelerdi(%34.8) ve sigara içme oranı %27,1 idi. Katılımcıların yaklaşık üçte biri (%31) daha önce bir COVID-19 enfeksiyonuna ve antikor pozitifliğine (%27.9) sahipti. En sık görülen yan etkilerin kol ağrısı (%55.8) olduğu, ardından baş ağrısı (%24.8), yorgunluk (%18.6) ve eklem ağrısı (%7.8) olduğu belirlendi. Aşılamadan sonraki üçüncü günde bir kişide COVID-19 teşhisi konuldu. Dördü (%0,8) senkop, bir kişi ise COVID-19 nedeniyle günlük işlerine ara verdiklerini belirtti. Sonuç: Çalışmamızda CoronaVac aşısının erken yan etkileri arasında en sık görülen yan etkiler Kol ağrısı, Baş Ağrısı, Yorgunluk ve Eklem ağrılarıydı. Gönüllülerimizde hayatı tehdit eden herhangi bir yan etki görmedik. Aşılama sıklığını artırmak ve COVID-19 aşısıyla ilgili endişeleri gidermek için çok katmanlı ve kanıta dayalı stratejiler kullanmanın önemli olduğunu savunuyoruz. Aşılamayla ilgili yaygın bilgi kirliliğini ve düşmanlığı en aza indirmek için sağlık profesyonelleri aşı programlarına liderlik etmeli ve güçlü bir şekilde desteklemelidir.

Anahtar Kelimeler

• CoronaVac
• COVID-19
• aşılanma
• SARS-CoV-2
• yan etkiler

Kaynakça

1. 1. Lu R, Zhao X, Li J, et al. (2020) Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395:565–574. https://doi.org/10.1016/S0140-6736(20)30251-8.
2. 2. World Health Organization (2020). WHO coronavirus disease (COVID-19) dashboard. https://covid19.who.int. Accessed January 19, 2021.
3. 3. Wu Z, Hu Y, Xu M, et al. (2021) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. https://doi.org/10.1016/s1473-3099(20)30987-7.
4. 4. World Health Organization (2021). Draft landscape of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed January 15, 2021.
5. 5. Züst R, Cervantes-Barragán L, Kuri T, et al. Coronavirus non-structural protein 1 is a major pathogenicity factor: Implications for the rational design of coronavirus vaccines. PLoSPathog2007;3:1062–1072.
6. 6. Uddin KN. Corona vaccine. BIRDEM Med J 2020;11:1–5.
7. 7. Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 2020;369:77–81.
8. 8. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2021;21:39–51.

9. 9. Che Y, Liu X, Pu Y, et al. Randomized, Double-Blinded, Placebo-Controlled Phase 2 Trial of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in Healthy Adults. Clin Infect Dis 2020;ciaa1703.
10. 10. Xia S, Duan K, Zhang Y, et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA - J Am Med Assoc 2020;324:951–960.
11. 11. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021;21:181–192.
12. 12. Andre F, Booy R, Bock H, et al. Vaccination greatly reduces disease, disability, death, and inequity worldwide. Bull World Health Organ 2008;86:140–146.
13. 13. Siciliani L, Wild C, McKee M, et al. Strengthening vaccination programs and health systems in the European Union: A framework for action. Health Policy (New York) 2020;124:511–518. 14. Pogue K, Jensen JL, Stancil CK, et al. Influences on Attitudes Regarding Potential COVID-19 Vaccination in the United States. Vaccines 2020;8:582.
14. 15. Malik AA, McFadden SAM, Elharake J et al. Determinants of COVID-19 vaccine acceptance in the US. EClinicalMedicine2020;26:100495.
15. 16. Lewis JR. What Is Driving the Decline in People’s Willingness to Take the COVID-19 Vaccine in the United States? JAMA Heal Forum 2020;1:e201393.
16. 17. Kreps S, Prasad S, Brownstein JS, et al. Factors Associated With US Adults' Likelihood of Accepting COVID-19 Vaccination. JAMA Netw open 2020;3:e2025594.
17. 18. Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated? Vaccine2020;38:6500–6507.
18. 19. MacDonald NE, Eskola J, Liang X, et al. Vaccine hesitancy: Definition, scope and determinants. Vaccine 2015;33:4161–4164.
19. 20. Brunson EK, Schoch-Spana M. A Social and Behavioral Research Agenda to Facilitate COVID-19 Vaccine Uptake in the United States. Heal Secure 2020;18:338–344.
20. 21. Jacobson RM, St. Sauver JL, Finney Rutten LJ. Vaccine hesitancy. Mayo Clin Proc 2015;90:1562–1568.
21. 22. Expectations for a COVID-19 Vaccine. In: Assoc. Press. 2020. https://apnorc.org/projects/expectations-for-a-covid-19-vaccine.
22. 23. May 25-28, Washington Post-ABC News poll. In: Washington Post. 2020. https://www.washingtonpost.com/context/may-25-28-2020-washington-post-abc-news-poll/bb30c35e-797e-4b5c-91fc-1a1cdfbe85cc/. Accessed July 5, 2020.
23. 24. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N Engl J Med 2021;384:533–540.
24. 25. Spellberg B, Nielsen TB, Casadevall A. Antibodies, Immunity, and COVID-19. JAMA Intern Med.Published online Nov 24, 2020. https://doi.org/10.1001/jamainternmed.2020.7986.
25. 26. Dörner T, Radbruch A. Antibodies and B Cell Memory in Viral Immunity. Immunity 2007;27:384–392.
26. 27. Ylitalo KR, Lee H, Mehta NK. Health care provider recommendation, human papillomavirus vaccination, and Race/Ethnicity in the US national immunization survey. Am J Public Health 2013;103:164–169.
27. 28. Darden PM, Thompson DM, Roberts JR, et al. Reasons for not vaccinating adolescents: National immunization survey of teens, 2008-2010. Pediatrics 2013;131:645–651.
28. 29. Jackson DN, Peterson EB, Blake KD, et al. Americans' Trust in Health Information Sources: Trends and Sociodemographic Predictors. Am J Heal Promot2019;33:1187–1193.